Achieve Life Sciences’ Groundbreaking Second, Confirmatory Topline Data

Today Achieve Life Sciences announced groundbreaking topline data from our second, confirmatory Phase 3 ORCA-3 clinical study. The statistically significant results demonstrate that cytisinicline may be a safe and effective smoking cessation aid. Cytisinicline demonstrated 6 times greater likelihood of continuous smoking cessation at 6 months compared to placebo. Cytisinicline was also well tolerated, with low rates of adverse events reported. 

Smoking continues to be a major public health issue in the United States with more than 28 million adults who currently smoke cigarettes. Smoking is the leading cause of preventable death and disease, claiming the lives of an estimated 8 million people annually worldwide. Despite this alarming statistic, no new treatments to help people quit smoking have been approved in nearly 20 years.  

Quitting smoking is difficult, and few treatment options are available. These options often have limitations that lead to lack of adoption or early discontinuations, ultimately impacting the medication’s effectiveness. Our new Phase 3 data, along with the robust body evidence we now have, reinforce our belief in the potential impact cytisinicline could have on improving the lives of the millions of people who smoke that want to quit.  

We look forward to furthering our discussions with the FDA and with potential partners in hopes of bringing cytisinicline forward as a new gold standard for the treatment of smoking cessation.  

To learn more about our confirmatory Phase 3 topline results, click here: https://achievelifesciences.com/achieve-reports-statistically-significant-confirmatory-phase-3-results/